Filter ALL the bannerfags
Filter her. lol
I don't think that's true.
I was invested in 2010. And then I watched the DS destroy America in 2012.
Then I needed a break. You can only swim upstream for so long before you get tired.
Now I'm back and the upstream steam seems manageable.
But people get tired, anon.
That's just the truth.
mRNA Vaccines… 1/3
Let's start with the basics straight out of Wikipedia:
An RNA vaccine or mRNA (messenger RNA) vaccine is a new type of vaccine thattransfers molecules of synthetic RNA into human cells. Once inside the cells, the RNA functions as mRNA,reprogramming the cells to make the foreign protein that would normally be produced by the pathogen(e.g. a virus), or by cancer cells.
These protein molecules then stimulate an adaptive immune response that teaches the body to destroy any pathogen, or cancer cells, with the protein.[1] The mRNA molecule is coated with a drug delivery vehicle, usually PEGylated lipid nanoparticles, to protect the fragile mRNA strands, and aid their absorption into the human cells.[2][3][4]
Theadvantagesof RNA vaccines over traditional protein vaccinesinclude production speed and low cost of production,[5][6] and the induction of cellular immunity as well as humoral immunity.[7][8]Given the novel nature of the mechanism of action of RNA vaccines, and their delivery systems,[2] little is known about the medium and longer-term side effects,[8] however, autoimmunity, and reactogenicity (mainly from the lipid nanoparticles), have been highlighted.[6][9][10]The fragility of the mRNA molecule requires cold chain distribution and storage, which may impair effective efficacy due to inadequate dosage(i.e molecule degrades before injection).[1][5][6]
mRNA Vaccines 2/3
https://en.wikipedia.org/wiki/RNA_vaccine#Side_effects_and_risks
Specific
mRNA strands in the vaccine may elicit an unintended immune reaction; to minimize this, mRNA vaccine sequences are designed to mimic those produced by mammalian cell (i.e. human cells).[5]
Some mRNA-based vaccine platforms induce potent interferon type I responses, which have been associated not only with inflammation but also potentially with autoimmunity. Thus, identification of individuals at an increased risk of autoimmune reactions (e.g Lupus) before mRNA vaccination can allow precautions to be taken.[6]
The risks associated with mRNA strands that did not manage to pass into a human cell are considered to be low, as the fragile mRNA molecule should be quickly broken down inside the body once its drug delivery system has eroded.[10]
The drug delivery system holding the mRNA molecule (protecting the fragile mRNA strands from being broken down by the body before they enter the human cell), are usually PEGylated lipid nanoparticles which can be reactogenic, triggering their own immune reactions, and causing damage to the liver at higher doses.[49]Strong reactogenic effects were reported in trials of novel COVID-19 RNA vaccines.[50]
mRNA Vaccines 3/3
Before 2020, no mRNA technology platform (drug or vaccine), had ever been authorized for use in humans, and thus there was the risk of unknown effects,[8] both short-term, and longer-term (e.g. autoimmune responses or diseases).[4][10][11] The 2020 coronavirus pandemic required the faster production capability of mRNA vaccines, and made them attractive to national health organisations, and led to debate about the type of initial authorization mRNA vaccines should get, including emergency use authorization or expanded access authorization, after the eight-week period post final human trials.[13][14]
In November 2020, Peter Hotez said of the emerging mRNA COVID-19 vaccines, "I worry about innovation at the expense of practicality",[1] while Michal Linial said, "I won't be taking it immediately – probably not for at least the coming year", and "We have to wait and see whether it really works".[10] However Linial also added, "Classical vaccines were designed to take 10 years to develop. I don’t think the world can wait for a classical vaccine".[10] Tal Brosh, the Head of Infectious Disease Unit at the Samson Assuta Ashdod Hospital said, "There is a race to get the public vaccinated, so we are willing to take more risks", and "We will have a safety profile for only a certain number of months, so if there is a long-term effect after two years, we cannot know," adding "but then we would have the coronavirus for two more years".[10]
In November 2020, The Washington Post reported on hesitancy amongst healthcare professionals in the United States to the novel mRNA vaccines, citing surveys which reported that: "some did not want to be in the first round, so they could wait and see if there are potential side effects",[12] and that "doctors and nurses want more data before championing vaccines to end the pandemic".[12]
In December 2020, Yossi Karko, director of the clinical research unit at Hadassah Medical Center, who ran mRNA trials, said, "The FDA has a mechanism of approving drugs and vaccines for emergency cases. What this means is that the FDA has initial safety data. But if this was a usual situation, the researchers would have followed the volunteers for at least two years before the vaccine was approved".[34]
https://en.wikipedia.org/wiki/RNA_vaccine#Side_effects_and_risks
Published: 12 January 2018
==mRNA vaccines — a new era in vaccinology
Norbert Pardi, Michael J. Hogan, Frederick W. Porter & Drew Weissman==
Ethics declarations
Competing interests
In accordance with the University of Pennsylvania policies and procedures and our ethical obligations as researchers, we report that Norbert Pardi, Michael J. Hogan and Drew Weissman are named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins and vaccines. We have disclosed those interests fully to the University of Pennsylvania, and we have in place an approved plan for managing any potential conflicts arising from licensing of our patents. Frederick Porter reports no competing financial interests.
https://www.nature.com/articles/nrd.2017.243
mRNA vaccines: intellectual property landscape
The patent-filing activity grew dramatically over the past 5 years for bothinfectious disease and cancer indications. The number of applications for infectious disease indications surpassed those for cancer over the past 3 years, which could reflect increased interest in vaccines following epidemic outbreaks of MERS-CoV, Ebola virus and Zika virus. In August 2019, Moderna received FDA Fast Track Designation for an investigational Zika virus vaccine (mRNA-1893) currently being evaluated in a phase I study.
https://www.nature.com/articles/d41573-020-00119-8
I saw that last weekend. kek
all I know is that it's not (you)
That's just personal shit. Like TV's and jewelry.
If you have a loan, your house is covered up to that amount at least.